期刊文献+

疏肝化痰法对乳腺不典型增生激素受体及基因蛋白表达的影响 被引量:5

下载PDF
导出
摘要 目的:观察疏肝化痰法对乳腺不典型增生患者雌、孕激素受体、基因蛋白表达的影响。方法:将90例患者分别分为两组,治疗组60例采用乳痛合剂治疗,对照组30例采用淀粉胶囊作为观察对照,治疗3个月。通过免疫组化法检测两组治疗前后乳腺不典型增生腺体细胞内雌、孕激素受体阳性强度及Her-2/neu,P53基因蛋白表达的变化。结果:治疗组能够降低乳腺局部雌、孕激素受体的阳性积分。治疗前后对照及组间比较均有显著性差异(P<0.05)。结论:应用疏肝化痰法治疗乳腺不典型增生能够通过降低乳腺内雌孕激素受体阳性积分而减少雌孕激素对相应乳腺不典型增生部位的刺激,该途径可能有助于控制甚至逆转乳腺不典型增生癌变进程。
出处 《湖北中医杂志》 2008年第2期16-17,共2页 Hubei Journal of Traditional Chinese Medicine
  • 相关文献

参考文献4

二级参考文献11

  • 1叶锋,黄冰.乳腺肿瘤中c—erbB—2癌基因产物的表达及意义[J].中华病理学杂志,1993,22(2):104-106. 被引量:25
  • 2.ZY/T001.1—001.9—94.中医病证诊断疗效标准[S].,..
  • 3吴阶平 黄家驷.外科学[M].北京:人民卫生出版社,1992.80.
  • 4Page DL. Cancer risk amessment in benign breast biopsies. Human Pathol,1986:17(8):871.
  • 5李树玲.乳腺癌.见:中华人民共和国医政司编,中国常见恶性肿瘤诊治规范(第八分册).北京:北京医科大学中国协和医科大学出版社,1991:25-58.
  • 6Gusterson BA, Callick WJ, Venter DJ, et al. Immunohistochemaical localization of C-erb B-2 in human breast carcinomas. Mol Cell Probes, 1988:2(1):383.
  • 7Slamon DJ, Clark GM, Wong SG, et al. Huamn breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogen. Science, 1987:235(4785):177.
  • 8Bacus SS, Ruby SG, Weinberg DS, et al.HER-2/neu oncoprotein expression and proliferation in breast cancer. Am J Pathol, 1990:0 137(1):103.
  • 9Hamna W. Kahn HJ, Andrulis i, et al- Distribution and patterns of staining of neu oncogene product in benign and malignant breast disesses. Mod Patbol, 1990: 3(4):455.
  • 10Lodato RF, Maguire HC, Greone MI, et al. Immunohistochemical evaluation of C-erb B-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of breast,Mod Pathol, 1990:3(4) :449.

共引文献7

同被引文献44

  • 1刘晓菲,宋爱莉,李静蔚,殷玉琨.莪术油对大鼠乳腺癌癌前病变MVD及相关调控因子VEGF/FLK表达的干预作用研究[J].中医药学报,2011,39(4):19-21. 被引量:15
  • 2刘晓菲,宋爱莉,李静蔚.乳腺癌癌前病变与血管生成的相关性探讨[J].中医药学刊,2006,24(6):1023-1024. 被引量:5
  • 3赵锡民,谌霓,赵大鹏.中药治疗乳腺组织增生220例[J].中国医药导报,2007,4(08Z):80-80. 被引量:2
  • 4Serrano, D. , I^izzeroni, M.,Zambon, G. F. . Efficacy of tamoxifenbased on cytochrome P450 2D6, CYP2C19 and SULTIAI genotype inthe Italian Tamoxifen Prevention Trial [ J ]. Pharmacogenomics Jour-nal,2011,11 (2) :100 - 107.
  • 5Naseemuddin,M.,Iqbal, A. ,Nasti,T. H. ,et al,Cell mediated im-mune responses through TLR4 prevents DMBA-induced mammarycarcinogenesis in mice[ J]. In J Cancer,2012,130(4) :765 -774.
  • 6Chun,Kyung-Soo,Langenbach,et al.The Prostaglandin E2Receptor,EP2,Regulate Survivin Expression Via an EGFR/STAT3 Pathway in UVB-Exposed Mouse Skin[J].Molecular Carcinogenesis,2011,50(6):439-448.
  • 7Ung N,Putoczki TL,Stylli SS,et al.Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity[J].Cancer Biol Ther,2014,15(5):623-632.
  • 8Samanta S,Sharma VM,Khan.Regulation of IMP3 by EGFR signaling and repression by ER:implication for triple negative breast cancer[J].Oncogene,2010,25(1):101-107.
  • 9Kang Y,Park MA,Heo SW,et al.The radio-sensitizing effect of xanthohμmol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells[J].Biochim Biophys Acta,2013,1830(3):2638-2648.
  • 10肖红,楼丽华,许红霞.30例乳腺囊肿伴不典型增生病免疫组化指标分析[J].现代中西医结合杂志,2008,17(15):2304-2305. 被引量:4

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部